Charles P, et al. - Experts compared the individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). Findings did not suggest a significant difference of AAV relapse rates between individually tailored and fixed-schedule rituximab regimens. Fewer rituximab infusions were received by the individually tailored-arm.